(Sarstedt, Germany) for platelet aggregation. Blood was drawn with special caution to avoid undesirable activation of circulating platelets. All platelet reactivity measurements were performed within 1 hour after blood collection.
Experimental protocol in volunteers Platelet aggregation and VASP measurement were performed using the same blood sample (baseline), while the remaining blood volume was incubated with 5 nmol/l cangrelor for 10 minutes at 37ºC prior to aggregation and VASP measurements (inhibition).
Experimental protocol in patients Blood for the study was collected before PCI in patients on 75 mg/d ASA alone (baseline). Coronary angiography was performed according to the current guidelines and stent implantation was performed in the culprit lesion. Patients were given 300 mg of clopidogrel and the second blood specimen was collected 24 hours after PCI (inhibition). Patients were excluded from the study if they received any platelet glycoprotein IIb/IIIa blocker during the PCI or if they were on oral anticoagulants.
Platelet inhibitors
We used clopidogrel (Plavix, Sanofi, United States) for in vivo study, and cangrelor (formerly AR-C69931MX, kindly provided by AstraZeneca, United Kingdom) for ex vivo study. Both are P2Y12 receptor inhibitors. Clopidogrel requires hepatic meta bolism to become an active form, while cangrelor is a short-acting intravenous direct antiplatelet agent. 7
Platelet aggregation Aggregation was determined in whole blood using Multiplate (Dynabyte, Germany), the five-channel aggregometer based on measurements of electric impedance, so called multi-electrode aggregometer (MEA). The measurements were performed according to the manufacturer's protocol. 8 Shortly, to evaluate effectiveness of cangrelor or clopidogrel, the whole blood sample (0.3 ml) was anticoagulated with hirudin (Sarstet, Germany), diluted 1:1 with 0.9% saline, preincubated for 10 minutes at 37ºC, and then supplemented with ADP (with the final concentration of 6.4 μmol/l) (Dynabyte, Germany).
Aggregation curves were registered and analyzed using Dynabyte software enabling the calculation of the total area under the aggregation curve (AUC) and the maximal value of platelet aggregation (A max ) expressed in arbitrary units of aggregation. The aggregation measurements were done in duplicate and the maximal interassay variability was 15%.
vAsP measurements To monitor specific platelet ADP receptor antagonists, we used VASP/P2Y 12 flow cytometry kit (BioCytex, France).
9,10 Under the test conditions, VASP correlates with the P2Y 12 receptor inhibition, while its nonphosphorylation There are tests that measure the overall platelet reactivity as well as tests that can specifically show the action of antiplatelet drugs. Both types showed some predictive value for future ischemic events. The most commonly used method is aggregometry modified with newer devices such as VerifyNow (Accumetrics, United States) or Multiplate (Dynabyte, Germany). There are also flow cytometry and bio chemical methods with determination of serum thromboxane B 2 levels. These methods have 2 weaknesses. First, most of them lack standardization (such as for example the inter national normalized ratio), so the results can vary from one laboratory to another. Second, the positive predictive value of these methods is quite low. On the other hand, if there would be an idea to individualize the antiplatelet therapy with the drug dose change, one should consider using more specific tests that evaluate the specific pathway of platelet activation blocked by a given drug. It should also be mentioned that there is currently no recommendation to assess the antiplatelet drug action on a routine basis, but numerous studies are underway. Researchers are particularly inter ested in the monitoring of antiplatelet actions of clopidogrel. 5 This drug is used in patients after myocardial infarction for secondary prevention of future ischemic events and after coronary artery angioplasty as the prevention of stent thrombosis. Its nonoptimal antiplatelet action has been shown to increase risk for subsequent stent thrombosis after percutaneous coronary inter vention (PCI). 6 Two methods that are most widely used to estimate clopidogrel action are platelet aggregometry and the vasodilator-stimulated phosphoprotein phosphorylation (VASP) assay. While adenosine-diphosphate (ADP)-induced aggregation assess the more general aspect of platelet receptor P2Y 12 blockade, the VASP assay aims at the specific intraplatelet pathway blocked by clopidogrel. Both methods showed the predictive value for future adverse events in cardiac patients; yet, there are between those 2 methods at the laboratory level. 2 The aim of the study was to compare the changes in platelet reactivity after the action of P2Y 12 receptor blockers as measured by aggregometry or using the flow cytometric VASP detection assay.
PAtIEnts And mEthods
The study included 17 healthy volunteers (12 men, 5 women; aged 41 ±10 years) and 12 patients (all men, aged 62 ±12 years) with stable coronary artery disease treated with elective PCI with stent implantation. None of the patients or healthy volunteers had used any drugs that could affect the platelet reactivity, including nonsteroidal drugs, for at least 7 days before the study. Individuals receiving acetylsalicylic acid (ASA) in the patient group were eligible.
Blood was collected into a vacuum tube containing 0.105 M buffered sodium citrate (Becton Dickinson, United Kingdom) for the VASP assay and into a vacuum tube containing hirudin high on-treatment platelet reactivity We defined the high on-treatment platelet reactivity when the result after P2Y 12 blockade was above the upper quartile separately for the group of patients and volunteers. This general cut-off value was applied in previous studies. 11
Ethics The study was performed according to the guidelines of the Helsinki Declaration for human research and approved by the committee on the Ethics of Research in Human Experimentation at the Medical University of Lodz (No. RNN/13/07/KB).
statistical analysis The Shapiro-Wilk's test was used to verify normal distribution of the data. For platelet aggregation and for the VASP assay, the data were analyzed using a nonparametric analysis of variance (Kruskal-Wallis test) and the all-pairwise comparison Connover--Inman test (data presented as median and interquartile range: from 25% quartile, lower quartile, to 75% quartile, upper quartile). The calculations were performed using the StatsDirect statistical software.
rEsuLts The clinical characteristics of the study groups are presented in tAbLE 1. The use of cangrelor and clopidogrel was associated with a significant inhibition of platelet reactivity, measured with the VASP assay and ADP-induced aggregation (tAbLE 2, FIGurEs 1-4). In both groups, the degree of inhibition was significantly greater when measured with the aggregation method (tAbLE 3, tAbLE 4, FIGurE 5). There were no differences in baseline platelet reactivity or inhibited platelet reactivity between the groups. The only significant (P <0.05) coefficient of correlation between the VASP assay and aggregation results was observed in volunteers after in vitro cangrelor use: r = 0.81 between PRI and A max and r = 0.68 between PRI and AUC.
We defined the high on-treatment platelet reactivity when the result after P2Y 12 blockade was above the upper quartile seperately for the group of patients and volunteers. Considering this definition, there were 3 patients and 3 volunteers with MEA AUC and A max and 3 patients and 5 volunteers with the VASP assay. The only significant state correlates with the active form of P2Y 12 receptors. Blood sample is first incubated with prostaglandin E 1 (PGE 1 ) alone or PGE 1 + ADP. After a cellular permeabilization, VASP, in its phosphorylated state, is labeled by immunofluorescence using a specific monoclonal antibody. Dual color flow cytometry analysis allows to compare the 2 tested conditions and to evaluate, for each sample, the capacity of ADP to inhibit VASP. A platelet reactivity index (PRI, %) was calculated using corrected mean fluorescence intensities in the presence of PGE 1 alone or PGE 1 + ADP. 10 This test was reproducible in our laboratory with the coefficient of variation for duplicate analysis of 5%.
The investigators of platelet reactivity (MEA and VASP) were blinded to the status of the tested samples. implanted stent, median (min-max) 1 (1-2) periprocedural complications, n (%) 0 (0) statins, n (%) 12 (100) β-blockers, n (%) 12 (100) ACEIs, n (%) 12 (100) oral antidiabetics, n (%) 3 (25) ARBs, n (%) 2 (17) proton-pump inhibitors, n (%) 12 (100) a 3 patients received 2 BMSs and 2 patients received 2 DESs, the rest received 1 stent
Abbreviations: ACEI -angiotensin-converting enzyme inhibitor, ARB -angiotensin receptor blocker, BMS -bare meta l stent, CABG -coronary artery bypass grafting, DES -drug-eluting stent, PCI -percutaneous coronary inter vention, SD -standard deviation There is still no consensus as to which platelet reactivity test is the most suitable for the measurement of clopidogrel effect. Two distinct questions that should be addressed are: which test is more appropriate for the evaluation of pharmacodynamic effects and which test could be more useful in the prediction of patient clinical outcomes. Bauman et al. 13 showed that the VASP method and the VerifyNow ADP test correlate most with active clopidogrel meta bolite levels, while the correlation of classic light transmittance with this metabolite aggregometry is weaker. On the other hand, Siller-Matula et al.
14 demonstrated that MEA high-sensitivity ADP (with addition of prostaglandin) was more predictive for future stent thrombosis in patients after coronary interventions than the VASP method.
There still remains the problem of test interchangeability. Lordkipanidze et al. 15 showed that there is hardly any significant correlation between 6 different tests used with regard to (P <0.05) Spearman coefficient of correlation was r = 0.78 for the comparison between MEA AUC and A max in patients and r = 0.59 for the same comparison in volunteers. There were no significant correlations between the VASP assay and MEA with regard to the detection of high on-treatment platelet reactivity (r = 0.56 for VASP and A max and r = 0.26 for VASP and AUC).
dIscussIon Our study showed that the use of P2Y 12 agonist (both clopidogrel in patients and cangrelor ex vivo in volunteers) results in a greater change in the MEA ADP-induced aggregometry para meters compared with the VASP method. This finding is in line with the results by Siller-Matula et al., 12 who showed that clopidogrel response in a group of patients on clopidogrel was strongest when measured with MEA ADP-induced aggregometry. We confirmed this finding and additionally showed that this is also true for direct intravenous P2Y 12 receptor agonist -cangrelor. FIGurE 2 PRI (%) determination using the VASP assay in each patient before and after clopidogrel ingestion (each line represents 1 patient) Abbreviations: see tAbLE 2 FIGurE 3 The change in platelet aggregation in each volunteer before and after blood incubation with cangrelor (each line represents 1 volunteer) Abbreviations: see tAbLE 2 FIGurE 4 PRI (%) determination using the VASP assay in each volunteer before and after blood incubation with cangrelor (each line represents 1 volunteer) Abbreviations: see tAbLE 2 FIGurE 1 The change in platelet aggregation in each patient before and after clopidogrel ingestion (each line represents 1 patient) Abbreviations: see tAbLE 2 μmol/l were used, but it should be mentioned that the MEA method is based on the principles of impedance aggregometry, while the latter concentrations were used in optical aggregometry. The MEA device allows for the changes of agonist concentration, but the current literature and the reference ranges provided by the manufacturer refer to the ADP concentration of 6.4 μmol/l. We thus decided to use the recommended concentration, but it shows that the platelet reactivity tests are hardly inter changeable even within the aggregation methods.
Recently, the concept of high on-treatment platelet reactivity has been developed. This condition, which is partly responsible for the worse outcome in cardiovascular patients, has not been clearly defined yet due to a number of factors. 17 For this reason, it is generally not recommended to perform routine platelet reactivity measurements, 18,19 although the results of the relevant studies will be published soon. In our study, we defined high on-treatment platelet reactivity when the result of a given test exceeded the upper quartile for the group. There was no significant correlation between the VASP assay and both MEA tests in identifying patients/volunteers with such platelet reactivity. Subjects with high on-treatment platelet reactivity detected by one test did not show the same when another test was used. This is in line with the study by von Beckerath et al., 16 in which the coefficient of correlation was 0.35 between MEA ADP AUC and the VASP method (r = 0.26 in our study). On the other hand, we observed a strong correlation between MEA AUC and MEA A max for the detection of high on-treatment platelet reactivity, but it is quite understandable and only confirms good adjustment of the MEA method.
One of the limitations of our study is the small number of subjects, but this is rather typical of this type of studies. Another limitation is the use of only 2 tests for comparisons, but according to the current literature, these 2 tests and VerifyNow seem to be the best choice for the estimation of P2Y 12 receptor functional blockade.
In conclusion, the change in ADP-induced aggregation with the use of MEA in response to P2Y 12 antagonists is greater than that observed using the VASP assay. The tests are not interchangeable because they measure different aspects of the P2Y 12 receptor blockade. the aspirin-induced effect. 15 We demonstrated that as for P2Y 12 receptor blockade, the strength of correlations between the results of various tests depends on the laboratory methodology. In our study, there was a fairly good association between PRI and A max and between PRI and AUC, but only after ex vivo cangrelor use and not in patients before and after clopidogrel.
In other studies, there was a weak but significant correlation between VASP and aggregation in patients treated with clopidogrel.
13,14,16 However, it rather confirms our results that while testing the effects of clopidogrel, these tests are hardly inter changeable.
The MEA method is fairly new and uses the ADP concentration of 6.4 μmol/l. In the majority of studies, ADP concentrations of 5 and 20 A b
FIGurE 5 Blood platelet reactivity inhibition monitored by MEA and the VASP assay in the presence of P2Y 12 platelet inhibitors (A -in vitro studies) and in patients after clopidogrel ingestion (B -ex vivo studies). Data shown as median (interquartile range) of % inhibition; for in vitro studies: a P <0.001 (AUC vs. VASP and A max vs. VASP); for ex vivo studies: b P = 0.045 (A max vs. VASP), c P = 0.001 (AUC vs. VASP). Abbreviations: ADP -adenosine diphosphate, MEA -multi-electrode aggregometer, others -see tAbLE 2 
